Diabetes, Vol 43, Issue 4 518-522, Copyright © 1994 by American Diabetes Association
Poly I:C induction of alpha-interferon in the diabetes-prone BB and normal Wistar rats. Dose-response relationships
DO Sobel, CH Ewel, B Zeligs, V Abbassi, J Rossio and JA Bellanti
Department of Pediatrics, Georgetown University School of Medicine, Washington, DC.
Although the administration of a fixed dose of the alpha-interferon
(alpha-IFN) inducer, polyinosinic polycytidilic acid (poly I:C),
accelerates the development of diabetes in DP-BB rats, no reports have
characterized the dose-response relationship of poly I:C with serum
alpha-IFN levels and the development of diabetes. This study examines the
dose-response relationships of poly I:C with the induction of serum
alpha-IFN and the development of diabetes in DP-BB and normal Wistar rats.
Also tested in this study is the hypothesis that the lack of development of
diabetes in poly I:C-treated normal Wistar rats is attributable to a
deficient alpha-IFN response. Using poly I:C doses of 0.5, 1.5, 5, and 10
micrograms/g body weight, a direct dose-response relationship was observed
in DP-BB rats with the serum alpha-IFN response. Moreover, all doses of
poly I:C accelerated the onset of diabetes in BB rats. Serum alpha-IFN
levels inversely correlated with time of onset of diabetes (P < 0.01).
Also, BB rats with higher levels of serum alpha-IFN were associated with
earlier onset of diabetes (P < 0.001). Poly I:C-induced serum alpha-IFN
levels were significantly lower in diabetic than in nondiabetic BB rats. In
normal Wistar rats, although all doses of poly I:C significantly increased
serum alpha-IFN levels, diabetes was not induced. The results of this study
indicate that poly I:C administration elevates serum alpha-IFN and
accelerates the development of diabetes in BB rats at even very low
doses.(ABSTRACT TRUNCATED AT 250 WORDS)